Derazantinib (ARQ-087) is an oral selective FGFR1-3 inhibitor, which has been evaluated in several phase I/II trials, including advanced/inoperable CCA with FGFR2 gene fusion with ORR of 20.7% and DCR of 82.9% [99]. Here, FGFR2 is linked to cholangiocarcinoma.